Open Trials

 

 


 

Ovar

AGO-PRO 1 / Symptom Benefit

Does Palliative Chemotherapy Improve Symptoms in Women with Recurrent Ovarian Cancer? 

 

 

Download

AGO-PRO 1 / Symptom Benefit German Synopsis>>

 

AGO-OVAR 17  

A prospective randomised Phase III trial to evaluate optimal treatment duration of first-line bevacizumab in combination with carboplatin and paclitaxel in  patients with primary epithelial ovarian, fallopian tube or peritoneal cancer. The BOOST (Bevacizumab Ovarian Optimal Standard Treatment) Trial

 

 

Download

AGO-OVAR 17 German Synopsis>>


 

Ovar/Endometrium

AGO-GYN 8

Efficacy, tolerability and safety of Temsirolimus in women with platinum-refractory ovarian carcinoma or advanced endometrial carcinoma

 

 

 

Download

AGO-GYN 8 German Synopsis>>


 

 

Clinical trials in surgical settings 

 

 

AGO-OVAR OP.4 / DESKTOP III

A randomized multicenter study to compare the efficacy of additional tumor debulking surgery versus chemotherapy alone for recurrent platinum-sensitive ovarian cancer

 

Download

AGO-OVAR OP.4 / DESKTOP III German Synopsis >>

Deutsche Version | Sitemap | Search | Imprint | Contact

© 2011 AGO Research GmbH | Admin-Login | Webdesign Hamburg